021-51111890
购物车（）
sales@molnova.cn
Indophagolin
CAS No. 1207660-00-1
Indophagolin ( —— )
产品货号. M23377 CAS No. 1207660-00-1
Indophagolin is a potent, indoline-containing autophagy inhibitor with IC50 of 140 nM.?
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 2MG | ￥1280 | 有现货 |
|
| 5MG | ￥1887 | 有现货 |
|
| 10MG | ￥2843 | 有现货 |
|
| 25MG | ￥4803 | 有现货 |
|
| 50MG | ￥6853 | 有现货 |
|
| 100MG | ￥9477 | 有现货 |
|
| 200MG | 获取报价 | 有现货 |
|
| 500MG | 获取报价 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称Indophagolin
-
注意事项本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断
-
产品简述Indophagolin is a potent, indoline-containing autophagy inhibitor with IC50 of 140 nM.?
-
产品描述Indophagolin is a potent, indoline-containing autophagy inhibitor with IC50 of 140 nM.?Indophagolin antagonizes the purinergic receptor P2X4 as well as P2X1 and P2X3 with IC50s of 2.71, 2.40 and 3.49 μM, respectively.
-
同义词——
-
通路Autophagy
-
靶点Autophagy
-
受体autophagy;P2X1;P2X3;P2X4
-
研究领域——
-
适应症——
化学信息
-
CAS Number1207660-00-1
-
分子量523.8
-
分子式C19H15BrClF3N2O3S
-
纯度>98% (HPLC)
-
溶解度DMSO:10 mM
-
SMILESO=S(C1=CC2=C(C=C1Br)CCN2C(C3CC3)=O)(NC4=CC=C(Cl)C(C(F)(F)F)=C4)=O
-
化学全称——
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1.Carnero Corrales MA, et al. Thermal proteome profiling identifies the membrane-bound purinergic receptor P2X4 as a target of the autophagy inhibitor indophagolin [published online ahead of print, 2021 Mar 9]. Cell Chem Biol. 2021;S2451-9456(21)00102-1.
产品手册
关联产品
-
Talarozole
Talarozole is an oral systemic all-trans retinoic acid metabolism blocking agent (RAMBA).
-
pocapavir
Pocapavir is an investigational enterovirus (EV) capsid inhibitor.
-
LYN-1604 2HCl 221675...
LYN-1604 is a novel ULK1 activator.It inducing cell death involved in ATF3, RAD21, and caspase3, accompanied by autophagy and apoptosis.LYN-1604, to be the best candidate for a ULK1 agonist.LYN-1604 induced cell death involved in ATF3, RAD21, and caspase3, accompanied by autophagy and apoptosis.LYN-1604 has potential for good therapeutic effects on TNBC by targeting ULK1-modulated cell death in vivo.
